Antihemophilic Factor
- Atc Codes:B02BD02
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Advate, Beriate P, Haemoctin, Helixate NexGen, Kogenate, Octanate, Recombinate Antihämophilie Faktor, Refacto; Belgium: Advate, Factane, Helixate NexGen, Kogenate, Octanate, Recombinate, Refacto AF; Bulgaria: Advate, Koate DVI, Kogenate, Octanate; Cyprus: Advate, Kogenate, Octanate, Recombinate; Czech Republic: Advate, Haemoctin, Helixate, Kogenate, Octanate, Recombinate, Refacto; Denmark: Advate, Helixate NexGen, Kogenate, Octanate, Refacto AF; Estonia: Advate, Recombinate, Haemoctin SDH, Helixate Nexgen, Kogenate, Octanate, Recombinate, Refacto; Finland: Advate, Amofil, Helixate Nexgen, Kogenate, Octafil, Refacto AF; France: Advate, Factane, Helixate NexGen, Kogenate, Octanate, Recombinate Antihämophilie Faktor, Refacto AF; Germany: Advate, Beriate P, Faktor VIII SDH, Haemoctin SDH, Helixate Nexgen, Kogenate, Octanate, Recombinate; Greece: Advate, Haemoctin, Helixate, Kogenate, Octanate, Recombinate; Hungary: Advate, Helixate NexGen, Kogenate, Recombinate; Ireland: Advate, Helixate NexGen, Kogenate, Octanate; Italy: Advate, Helixate NexGen, Kogenate; Latvia: Advate, Helixate NexGen, Kogenate, Octanate, Recombinate, Refacto; Lithuania: Advate, Haemoctin, Octanate, Recombinate; Luxembourg: Advate; Malta: Advate, Haemoctin; Netherlands: Aafact, Advate, Haemoctin, Helixate NexGen, Kogenate, Octanate, Recombinate; Poland: Advate, Czynnik VIII, Emoclot D.I., Helixate Nexgen, Kogenate, Octanate, Recombinate, Refacto; Portugal: Advate, Beriate P, Emoclot D.I., Factane, Haemoctin, Helixate NexGen, Kogenate, Octanate, Recombinate, Refacto AF; Romania: Advate, Emoclot, Haemoctin, Helixate NexGen, Kogenate, Octanate, Recombinate, Refacto AF; Slovakia: Advate, Beriate P, Helixate NexGen, Kogenate, Octanate, Recombinate, Refacto AF; Slovenia: Advate, Recombinate; Spain: Advate, Beriate P, Helixate NexGen, Kogenate, Octanate, Refacto AF; Sweden: Advate, Helixate Nexgen, Kogenate, Octanate, Recombinate; UK: Advate, Haemoctin, Helixate NexGen, Kogenate, Octanate, Refacto.
North America
Canada: Advate, Helixate FS, Kogenate FS; USA: Advate, Kogenate FS, Refacto, Xyntha.
Latin America
Brazil: Beriate P, Monoclate-P; Mexico: Beriate P, Monoclate-P, Octanate.
Asia
Japan: Advate, Kogenate FS, Recombinate.
Drug combinations
Chemistry
Pharmacologic Category
Antihemorrhagic Agents; Hemostatics. (ATC-Code: B02BD02).
Mechanism of action
Protein (factor VIII) in normal plasma which activates factor X. Activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin. Forms a stable clot with factor XIII.
Therapeutic use
Prevention and treatment of hemorrhagic episodes in hemophilia A.
Pregnancy and lactiation implications
Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to any component of the formulation.
Warnings and precautions
Possible anemia and intravascular hemolysis in blood groups A, B, and AB when large or frequently repeated doses are administered (contains trace amounts of blood groups A and B isohemagglutinins). Formulations contain human albumin and may contain trace amounts of mouse protein. Product of human plasma (may potentially contain infectious agents which could transmit disease). Packaging may contain natural rubber latex. Products contain naturally-occurring von Willebrand factor for stabilization.